BCM
INKT icon

Bridgeway Capital Management’s MiNK Therapeutics INKT Stock Holding History

Bridgeway Capital Management’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,550
Closed -$50K – 1426
2022
Q2 		$50K Hold
3,550
– – ﹤0.01% 1281
2022
Q1 		$80K Buy
+3,550
New +$107K ﹤0.01% 1272

Other funds holding INKT

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bridgeway Capital Management's INKT Position: Q3 2022 in Review

Bridgeway Capital Management sold out of MiNK Therapeutics (INKT) in Q3 2022, closing a stake of 3,550 shares — an estimated $50K sold.

Bridgeway Capital Management first reported a position in INKT in Q1 2022 and held it in 2 quarters. The position peaked at $80K in Q1 2022. 11 funds tracked by Wall St. Rank hold INKT as of Q3 2022.

  • Bridgeway Capital Management reported no remaining MiNK Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Bridgeway Capital Management sold 3,550 MiNK Therapeutics shares in Q3 2022, an estimated $50K.
  • Bridgeway Capital Management first reported a position in MiNK Therapeutics in Q1 2022 and held it in 2 quarters.
  • Bridgeway Capital Management's MiNK Therapeutics position peaked at $80K in Q1 2022.
  • 11 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q3 2022.

Based on Bridgeway Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.